Skip to Content

Generic Balcoltra Availability

Balcoltra is a brand name of ethinyl estradiol/levonorgestrel, approved by the FDA in the following formulation(s):

BALCOLTRA (ethinyl estradiol; levonorgestrel - tablet;oral)

  • Manufacturer: AVION PHARMS
    Approval date: January 9, 2018
    Strength(s): 0.02MG;0.1MG

Has a generic version of Balcoltra been approved?

No. There is currently no therapeutically equivalent version of Balcoltra available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Balcoltra. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Enhancing solubility of iron amino acid chelates and iron proteinates
    Patent 6,716,814
    Issued: April 6, 2004
    Inventor(s): Clayton; Ericson & H. DeWayne; Ashmead
    Assignee(s): Albion International, Inc.

    A method of enhancing the solubility of iron amino acid chelates and iron proteinates is disclosed. This is accomplished by mixing an effective amount of an organic acid solubilizing agent into existing iron amino acid chelates or iron proteinates. The iron amino acid chelates and iron proteinates may have a ligand to metal molar ratio from about 1:1 to 4:1, preferably 2:1 to 3:1.

    Patent expiration dates:

    • August 16, 2021
      ✓ 
      Drug substance
      ✓ 
      Drug product

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Glossary
TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
Hide